Mildronate (Meldonium Dihydrate)

Meldonium inhibits the enzyme gamma‑butyrobetaine hydroxylase, which is essential for carnitine synthesis. Lower carnitine levels shift myocardial and neuronal cells from fatty‑acid oxidation toward glucose oxidation, a more oxygen‑efficient pathway. This metabolic reprogramming enhances ATP production during low‑oxygen states, protecting tissue from ischemic damage.

The dosage of Mildronate is individualized by the prescribing physician based on the patient’s clinical condition, severity of disease, and response to therapy. Healthcare professionals determine the appropriate strength, frequency, and duration of treatment, and patients should follow the prescriber’s instructions without self‑adjusting the dose.

Safety data for Meldonium in pregnancy and lactation are limited. The drug should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Physicians are advised to discuss the uncertainties with patients and consider alternative therapies when appropriate.

To request Mildronate, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, confirming trade or institutional credentials before providing a formal quote, availability, shipping details, and any necessary import documentation.

Mildronate differs from traditional anti‑ischemic drugs such as nitrates or beta‑blockers by targeting cellular metabolism rather than vascular tone. While nitrates dilate vessels and beta‑blockers reduce heart rate, Meldonium enhances myocardial energy efficiency, offering a complementary mechanism that may be used alongside standard therapies under medical supervision.

Mildronate tablets should be stored at room temperature, below 25 °C, in the original packaging. Protect the product from moisture, excessive heat, and direct sunlight to maintain stability and potency throughout its shelf life.

Mildronate is supplied as an oral tablet and is taken by mouth with water. The exact timing—whether with meals or on an empty stomach—depends on the prescriber’s guidance, which takes into account the patient’s overall treatment plan and tolerability.

Serious adverse events, although rare, include severe hypotension, cardiac arrhythmias, allergic reactions such as rash or swelling, and significant elevations in liver enzymes. Patients should seek immediate medical attention if they experience sudden dizziness, palpitations, breathing difficulty, or signs of an allergic response.

Mildronate is contraindicated in individuals with known hypersensitivity to meldonium or any tablet excipients. Caution is also advised for patients with severe renal impairment, uncontrolled hypertension, or those taking medications that may cause additive hypotensive effects. The drug should be avoided in pregnant or nursing women unless clearly justified by a physician.